论文部分内容阅读
应用S－P免疫组化法对85例肺癌及25例肺良性疾病标本进行了P53蛋白及EGFR的检测。结果：P53蛋白在肺癌中的阳性率为50．6％（43／85）。鳞癌及大细胞癌阳性率显著高于腺癌及小细胞癌的阳性率（P＜0．05）。肺良性疾病标本均阴性。P53蛋白阳性者的淋巴结转移率（79．1％，34／43）显著高于P53蛋白阴性者的转移率（57．1％，24／42）（P＜0．05）。提示P53蛋白在肺癌的发生发展及转移中起重要作用。EGFR在肺癌中的阳性率为72．9％（62／85），而在肺良性病变中为12％（3／25），两者阳性率差异显著（P＜0．05）。EGFR过度表达与肺癌病理类型及是否发生转移均无相关性。肺癌癌旁组织EGFR阳性率65．3％（62／95）。增生组癌旁组织阳性率（81．0％，47／58）显著高于无增生组阳性率（40．5％，15／37）（P＜0．05），无增生组癌旁组织阳性率显著高于肺良性疾病阳性率（P＜0．05）。提示EGFR过度表达与癌旁组织的增生密切相关，可能是肺癌发生的早期事件，在肺癌的发生中起重要作用。P53蛋白及EGFR共同表达者淋巴结转移率（85．3％，29／34）显著高于非共同阳性者的转移率（48．8％，21／43）（P＜0．01）。因此，P53蛋白及EGFR共同阳性提示肺癌具有高度转移潜能，预后可能较差。
S-P immunohistochemistry was used to detect P53 protein and EGFR in 85 lung cancer patients and 25 lung benign diseases. Results: The positive rate of P53 protein in lung cancer was 50.6% (43/85). The positive rate of squamous cell carcinoma and large cell carcinoma was significantly higher than that of adenocarcinoma and small cell carcinoma (P<0.05). Benign lung disease specimens were negative. The lymph node metastasis rate of patients with positive P53 protein (79.1%, 34/43) was significantly higher than that of P53 protein negative (57.1%, 24/42) (P<0.05). It suggests that P53 plays an important role in the occurrence, development and metastasis of lung cancer. The positive rate of EGFR in lung cancer was 72.9% (62/85), while in lung benign disease it was 12% (3/25). The positive rate of EGFR was significantly different (P<0.05). There was no correlation between the overexpression of EGFR and pathological types of lung cancer and whether metastasis occurred. The positive rate of EGFR in lung cancer tissues was 65.3% (62/95). The positive rate of paracancerous tissues in the proliferative group (81.0%, 47/58) was significantly higher than that in the non-proliferative group (40.5%, 15/37) (P<0.05). The rate was significantly higher than that of benign lung disease (P<0.05). It suggests that overexpression of EGFR is closely related to the proliferation of adjacent tissues. It may be an early event of lung cancer and plays an important role in the development of lung cancer. The metastatic rate of lymph node metastasis (85.3%, 29/34) was significantly higher in patients with P53 protein and EGFR (48.8%, 21/43) than that in non-common positive patients (P<0.01). Therefore, the common positive expression of P53 protein and EGFR suggests that lung cancer has a high metastatic potential and the prognosis may be poor.